Efficacy and safety of treatment of patients suffering from severe forms of psoriasis

Abstract

A comparative clinical, laboratory and ultrasonic assessment of the efficacy and safety of Infliximab (Remicade®) and cyclosporine A as well as photochemotherapy on the basis of Oxsoralen in 90 patients suffering from severe plaque psoriasis and psoriatic erythroderma at the progression stage. Clinical and ultrasonic assessment demonstrated that Infliximab (Remicade®) is a highly efficient drug for treatment of severe plaque psoriasis and psoriatic erythroderma providing an evident reduction in inflammatory changes both in the epidermis and dermis as well as normalizing epidermal keratinization processes. A long-term maintenance treatment with Infliximab positively modifies the course of severe psoriasis in patients and is quite safe. A course of treatment with cyclosporine A and general photochemotherapy is quite efficient under similar conditions but its action is short-term. After the completion of the above-mentioned therapy, patients develop dermatosis relapses of the same severity and extent during a year of follow-up. According to the ultrasonic examination results, a course of treatment with cyclosporine A and photochemotherapy has a partial effect on pathohistology processes in psoriatic patients as well as entails a number of adverse effects.